ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0081

Prevalence of Systemic Autoimmune Diseases in Polycystic Ovary Syndrome

Saika Sharmeen1, Hafsa Nomani2, Erin Taub3 and Qingping Yao3, 1Stony Brook University Renaissance School of Medicine, Dix Hills, NY, 2Stony Brook University Renaissance School of Medicine, West Babylon, NY, 3Stony Brook University Renaissance School of Medicine, Stony Brook, NY

Meeting: ACR Convergence 2020

Keywords: autoimmune diseases, Osteoarthritis, rheumatoid arthritis, sex hormones, Women's health

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Friday, November 6, 2020

Title: Miscellaneous Rheumatic & Inflammatory Diseases Poster I: Diagnosis and Testing

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Polycystic ovary syndrome (PCOS) is characterized by hormonal abnormality, chronic anovulation, hyperandrogenism, and obesity. Due to the hormonal imbalance, we hypothesize that patients with PCOS may tend to develop inflammatory and immune disorders. To test this hypothesis, we sought to examine the frequency of systemic autoimmune diseases in PCOS.

Methods: A retrospective chart review of patients in a single center between January 2004 and February 2020 was conducted after approval by the Institutional Review Board. There were two groups consisting of PCOS patients aged 18 and older and age- and BMI-matched patients without PCOS in a ratio of 1:2. Exclusion criteria were endometrial or ovarian cancer. Electronic medical records (EMRs) were searched for individual rheumatic and systemic autoimmune diseases using ICD-9 and ICD-10 codes and for laboratory data. A comparison between PCOS and non-PCOS subjects was made in relevant parameters followed by a subgroup analysis between these groups based on weight categories: obese (BMI >=30), overweight (BMI 25-30), and nonobese (BMI< 25). Fisher Exact, Chi-square, Wilcoxon rank sum and Kruskal Wallis tests were used for statistical analysis.

Results: There were a total of 2,262 patients including 754 PCOS and 1,508 non-PCOS as control. The study population included 12.8% nonobese, 22.6% overweight, and 64.7% obese females with median age of 30.0 years and median BMI of 33.1. The rheumatic disorders and relevant laboratory data were compared between the two groups and are summarized (Tables 1 and 2). Our study showed that the frequency of RA was 2.25% in PCOS group and 1.26% in control (p=0.0747). The prevalence of RA in PCOS group more than doubled that (1%) in the general population, suggesting PCOS patients may tend to develop seropositive/seronegative inflammatory arthritis.  There was no significant difference in positive RF (0.27% VS 0.33%, p=1.0) or CCP (0.27% VS 0.07%, p=0.26) between groups. Our study also showed that compared with non-PCOS group, both SSc (0.0% VS 0.04%, p=0.0369) and UCTD (0.0% VS 0.53%, p=0.0123) were more prevalent in PCOS patients. Interestingly, PCOS patients were more likely to have ANA (11.41% VS 7.56%, p=0.0024) and ESR tested (19.10% VS 13.13%, p=0.0002) compared to controls. However, there was no significant difference in the positivity rate of ANA and other serologic markers between the two groups even with subgroup analysis of weight categories.  PCOS patients had significantly higher frequency of OA than non-PCOS patients (5.44% VS 2.92%, p=0.0030).

Conclusion: For the first time, our study suggests that PCOS patients may have higher frequency of systemic autoimmune diseases (seropositive/seronegative RA, SSc, and UCTD). The study is limited due to the inherent weakness of a retrospective study and search methodology using ICD codes. Future multicenter study with a larger sample size would be needed to validate the significance of our findings.

*Statistical comparison of percentage of positives between patients with PCOS and patients without.

RA=Rheumatoid Arthritis; SLE=Systemic Lupus Erythematosus; UCTD=Undifferentiated Connective Tissue Disease; SSc=Systemic Sclerosis; OA=Osteoarthritis


Disclosure: S. Sharmeen, None; H. Nomani, None; E. Taub, None; Q. Yao, None.

To cite this abstract in AMA style:

Sharmeen S, Nomani H, Taub E, Yao Q. Prevalence of Systemic Autoimmune Diseases in Polycystic Ovary Syndrome [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/prevalence-of-systemic-autoimmune-diseases-in-polycystic-ovary-syndrome/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-of-systemic-autoimmune-diseases-in-polycystic-ovary-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology